PHARMACOLOGICAL AND PHARMACOECONOMIC ASSESSMENTS ON THERAPEUTIC EQUIVALENCE OF ANTI-HCV DRUGS
HEPATITIS C - HCV
The new challenge for this decade is to understand which strategy should be implemented to continue the HCV elimination plan in Italy, considering separate factors: on the one hand the further expansion of patient recruitment criteria by AIFA (to date 12) and on the other the conclusion of the three-year period of innovative status with the consequent exit from the innovative drugs fund.
Scarica PDF
Luglio 2020